Recent Articles

September 28, 2017 12:00 pm
Ryan Bushey, Digital Editor, Drug Discovery & Development
Axovant’s therapy, intepirdine, did not produce improvements in cognition or in measures of activities of daily living for patients with mild to moderate Alzheimer’s disease who were receiving background therapy with another Alzheimer’s drug called donepezil.
August 30, 2017 2:38 pm
Joanne Van Zuidam, Editor, Drug Discovery & Development
The U.S. Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).
August 21, 2017 9:08 am
Andrea Toel, Senior Product Manager, Lonza
Here we explore how the development of cancer immunotherapies has started to focus on improving efficiency, safety, and specificity by using genetic engineering approaches.
Subscribe to Bioscience Technology